Open an account

Carlsmed

CARL · NASDAQ

$14.18+$0.52 (+3.81%)TodayMarket closed ·
Prev close $13.66

About CARL

Carlsmed, Inc. engages in the development of AI based technology solutions to the medical industry. The company is headquartered in Carlsbad, California and currently employs 127 full-time employees. The company went IPO on 2025-07-23. Its aprevo technology platform offers solutions for the entire surgical workflow, including pre-operative AI-enabled, surgical planning; intra-operative advanced visualization to support precision placement of aprevo interbody implants, and post-operative data collection and insights for each surgeon. Its pre-operative planning software utilizes standard-of-care diagnostic imaging and AI-enabled algorithms to develop personalized digital surgical plans and to design aprevo interbody implants for each patient's pathology and vertebral bone topography. Additionally, the aprevo technology platform supports the collection of real-world, post-operative data to inform its digital surgical planning process. Its platform is commercially available in the United States and is indicated for use in lumbar interbody fusion procedures.

Employees
127
Headquarters
Carlsbad, California
Listed
Jul 23, 2025
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
carlsmed.com

CARL key statistics

Market cap
387.15M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
71.98K
Volume
50.73K
Open price
$13.69
High today
$14.43
Low today
$13.53
52 Week high
$17.23
52 Week low
$8.50

Carlsmed (CARL) at a glance

As of Oct 20, 2026, Carlsmed (CARL) shares are priced at $14.18, giving the company a market cap of 387.15M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $13.53 and $14.43. The current price is 4.8% above the day's low and 1.7% below its high.

Volume so far is 50.73K shares, below the average of 71.98K shares a day.

Over the past year Carlsmed has ranged from $8.50 to $17.23, and now sits 65% of the way up that range.

Carlsmed met or beat analyst EPS estimates in 4 of the last 4 quarters. In Q2 FY26 it reported -$0.39 per share against an estimate of -$0.4162.

The average analyst price target is $19.58, 38.1% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $19.58
Low
$17.17
Now
$14.18
High
$24.15

CARL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 4 quarters, by 16.6% on average.

  1. Q3 FY25: reported -$0.40 per share against an estimate of -$0.4631
  2. Q4 FY25: reported -$0.32 per share against an estimate of -$0.4345
  3. Q1 FY26: reported -$0.32 per share against an estimate of -$0.3998
  4. Q2 FY26: reported -$0.39 per share against an estimate of -$0.4162

CARL news

  • Vandana Singh

    Carlsmed Unveils Custom Cervical Plating Tech

  • Earnings Scheduled For November 6, 2025

  • Vandana Singh

    Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage

  • Press releaseBusiness Wire

    Carlsmed Announces Pricing of Initial Public Offering

  • Press releaseBusiness Wire

    Carlsmed Announces Launch of Initial Public Offering

Similar companies

Companies in the same industry as Carlsmed

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.